Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals, Inc. (CYCC) Healthcare & Pipeline Overview

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing treatments for various cancers and diseases involving abnormal cell growth. Its pipeline includes CDK and PLK inhibitors, with candidates like Fadraciclib and CYC140 in Phase 1/2 trials, targeting solid tumors and hematological malignancies.

What Is the Investment Thesis for CYCC?

Cyclacel Pharmaceuticals, Inc. presents a research-stage investment profile centered on its clinical-stage pipeline of novel cancer therapies. The company's primary value drivers are the progression and potential success of its drug candidates, Fadraciclib, CYC140, and Sapacitabine, all currently in Phase 1/2 clinical trials for various hematological malignancies and solid tumors. Positive clinical trial results and subsequent regulatory advancements represent key growth catalysts, potentially leading to significant value inflection points. The strategic collaboration with the University of Texas MD Anderson Cancer Center further validates its compounds and provides a robust platform for clinical evaluation. However, as a clinical-stage biopharmaceutical firm with a market capitalization of $10.61M and a profit margin of -204.2%, Cyclacel faces inherent risks associated with drug development, including high attrition rates, the need for substantial capital, and the uncertainty of regulatory approvals. Its gross margin of 18.4% reflects some operational activity but underscores its pre-revenue stage. The company's future performance is directly tied to its ability to successfully navigate clinical trials, secure funding, and eventually commercialize its drug candidates, making ongoing monitoring of trial results and financial runway critical for analysis.

Based on FMP financials and quantitative analysis

CYCC Key Highlights

• Market Capitalization: $0.01 billion, reflecting its early-stage development and focus on research and clinical trials.
• Profit Margin: -204.2%, indicative of a company in the R&D phase without significant product revenue, typical for clinical-stage biotechs.
• Gross Margin: 18.4%, suggesting some operational activity or early-stage revenue, though not yet profitable.
• Beta: 0.16, indicating lower volatility compared to the broader market, potentially due to its clinical-stage nature and specific news drivers.
• Employee Count: 12 employees, a lean operational structure supporting its specialized biopharmaceutical research and development efforts.

Who Are CYCC's Competitors?

CYCC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CYCC's Key Strengths?

• Diverse pipeline of clinical-stage drug candidates targeting multiple cancer types and other diseases.
• Strategic collaboration with a renowned institution, the University of Texas MD Anderson Cancer Center, validating research.
• Focus on novel mechanisms of action, such as CDK and PLK inhibition, which are key areas in targeted cancer therapy.
• Inclusion of an orally available nucleoside analog (Sapacitabine) in the pipeline, offering potential patient convenience.
• Lean operational structure with 12 employees, potentially allowing for agile R&D.

What Are CYCC's Weaknesses?

• Operating at a significant net loss with a profit margin of -204.2%, indicating high R&D costs and no substantial revenue.
• Clinical-stage company with no commercialized products, leading to inherent financial uncertainty and reliance on external funding.
• Small employee base of 12, which may limit the scope and speed of parallel development activities.
• High attrition rate inherent in pharmaceutical development, where many drug candidates fail in clinical trials.
• Limited financial resources compared to larger pharmaceutical competitors.

What Could Drive CYCC Stock Higher?

• Clinical trial progress for Fadraciclib in Phase 1/2 studies for solid tumors and in combination with venetoclax for chronic lymphocytic leukemia.
• Advancement of CYC140 through Phase 1/2 clinical trials for advanced leukemias and solid malignancies.
• Continued evaluation of Sapacitabine in Phase 1/2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome.
• Release of interim or final data from ongoing Phase 1/2 clinical trials for Fadraciclib, CYC140, and Sapacitabine, which could provide insights into efficacy and safety.
• Further updates on investigator-sponsored trials (ISTs) for Seliciclib in Cushing's disease and advanced rheumatoid arthritis, potentially indicating new therapeutic avenues.

What Are the Key Risks for CYCC?

• Negative return on equity (-51.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• High attrition rate inherent in pharmaceutical development, where a significant percentage of drug candidates fail in clinical trials.
• Financial sustainability challenges, given the company's negative profit margin of -204.2% and reliance on external funding for R&D.
• Regulatory hurdles and delays in obtaining necessary approvals from health authorities for any of its drug candidates.
• Intense competition from larger pharmaceutical companies and other biotechnology firms with more extensive resources and pipelines.
• Clinical trial failures due to lack of efficacy, unexpected adverse events, or inability to meet primary endpoints.

What Are the Growth Opportunities for CYCC?

• Growth opportunity 1: Advancement of Fadraciclib in Solid Tumors and CLL. Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently in Phase 1/2 clinical studies for solid tumors and in combination with venetoclax for relapsed/refractory chronic lymphocytic leukemia (CLL). Successful progression through these trials, demonstrating favorable safety and efficacy profiles, could unlock significant market potential. The global market for solid tumor treatments is substantial, and effective therapies for resistant CLL patients represent a critical unmet need. Positive outcomes could attract licensing partners or facilitate further development, potentially leading to market entry in the long term, contingent on successful Phase 3 trials and regulatory approvals.
• Growth opportunity 2: Development of CYC140 for Leukemias and Solid Malignancies. CYC140, a polo-like kinase (PLK) inhibitor, has progressed to Phase 1/2 clinical trials for advanced leukemias and solid malignancies. PLK inhibitors are a class of drugs targeting cell cycle regulation, a fundamental process in cancer. Demonstrating efficacy in these early-stage trials could position CYC140 as a novel treatment option for difficult-to-treat cancers. The market for advanced leukemia treatments, including acute myeloid leukemia, is a high-need area. Successful clinical development could lead to a differentiated product in a competitive landscape, with potential long-term revenue generation upon approval.
• Growth opportunity 3: Clinical Progression of Sapacitabine in AML and MDS. Sapacitabine, an orally available nucleoside analog, is in Phase 1/2 clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Both AML and MDS are severe hematological disorders with limited treatment options, particularly for patients who are elderly or unfit for intensive chemotherapy. An orally available therapy with a favorable safety and efficacy profile could significantly improve patient convenience and outcomes. Positive data from these trials would be a major catalyst, potentially accelerating its path through later-stage development and addressing a significant patient population in the long term.
• Growth opportunity 4: Expansion of Seliciclib's Therapeutic Applications. Seliciclib, another CDK inhibitor, is being investigated in investigator-sponsored trials (ISTs) for indications beyond oncology, specifically a Phase 2 study for Cushing's disease and a Phase 1/2 study for advanced rheumatoid arthritis. This diversification into non-oncology areas represents a potential expansion of Cyclacel's addressable market. Cushing's disease is a rare endocrine disorder, and advanced rheumatoid arthritis affects a large patient population. Successful outcomes in these ISTs could open new development pathways and partnerships, offering long-term growth opportunities by leveraging existing compounds in new therapeutic areas.
• Growth opportunity 5: Strategic Alliance with MD Anderson Cancer Center. The collaboration with the University of Texas MD Anderson Cancer Center is a significant growth driver. This partnership allows for the clinical assessment of three of Cyclacel's compounds in various blood cancers, including chronic lymphocytic leukemias, acute myeloid leukemias, and myelodysplastic syndromes. Leveraging MD Anderson's expertise and patient access can accelerate clinical trial enrollment and provide robust data, enhancing the credibility and development speed of Cyclacel's pipeline. This alliance could lead to more efficient clinical development, potentially reducing the time and cost to bring new therapies to market in the long term.

What Opportunities Does CYCC Have?

• Successful progression of Fadraciclib, CYC140, and Sapacitabine through later-stage clinical trials and regulatory approval.
• Expansion of Seliciclib's applications into non-oncology areas like Cushing's disease and rheumatoid arthritis, broadening market potential.
• Formation of additional strategic partnerships or licensing agreements to accelerate development and commercialization.
• Addressing significant unmet medical needs in specific cancer types and rare diseases, potentially leading to premium pricing and market share.
• Potential for orphan drug designations for specific indications, offering regulatory and market exclusivity benefits.

What Threats Does CYCC Face?

• Failure of drug candidates in clinical trials due to lack of efficacy or unacceptable safety profiles.
• Intense competition from larger pharmaceutical companies and other biotechnology firms developing similar or superior therapies.
• Regulatory hurdles and delays in obtaining necessary approvals from health authorities.
• Inability to secure sufficient funding to continue research and development activities.
• Patent expirations or challenges to intellectual property protecting its drug candidates.

What Are CYCC's Competitive Advantages?

• Proprietary pipeline of novel small molecule drug candidates, including specific CDK and PLK inhibitors, targeting unique mechanisms of action.
• Clinical-stage development progress, with multiple compounds already in Phase 1/2 trials, representing significant R&D investment and intellectual property.
• Strategic collaboration with the University of Texas MD Anderson Cancer Center, providing access to specialized clinical expertise and patient populations for accelerated development.
• Focus on specific, high-need indications within oncology and other proliferative diseases, potentially addressing unmet medical needs.
• Expertise in developing orally available nucleoside analogs, offering potential advantages in patient convenience and compliance.

What Does CYCC Do?

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company operating in the clinical development stage, dedicated to the discovery and advancement of innovative therapeutic solutions for various cancers and other diseases characterized by abnormal cell proliferation. Founded with a mission to address significant unmet medical needs in oncology, the company has strategically built a pipeline of drug candidates targeting critical cellular pathways involved in cancer progression. Its headquarters are located in Berkeley Heights, New Jersey, from where it manages a lean team of 12 employees focused on research and development. The company's active drug pipeline features several promising compounds. Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical studies for solid tumors. Additionally, Fadraciclib is being evaluated in combination with venetoclax for patients suffering from chronic lymphocytic leukemia (CLL) that has recurred or demonstrated resistance to prior therapies. Another key candidate, CYC140, a polo-like kinase (PLK) inhibitor, has advanced to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies. Sapacitabine, an innovative orally available nucleoside analog and prodrug of CNDAC, is also in Phase 1/2 clinical trials, specifically targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Beyond these, the pipeline includes Seliciclib, another CDK inhibitor, which is being investigated in investigator-sponsored trials (ISTs). These ISTs encompass a Phase 2 study for Cushing's disease and a Phase 1/2 study for advanced rheumatoid arthritis, showcasing the potential broader applicability of its compounds. A significant strategic alliance for Cyclacel is its collaboration with the University of Texas MD Anderson Cancer Center. This partnership is designed to clinically assess the safety and therapeutic potential of three of Cyclacel's compounds in patients afflicted with a spectrum of blood cancers, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced forms of leukemia. This collaborative approach underscores Cyclacel's commitment to rigorous clinical evaluation and its focus on addressing complex oncological challenges.

What Products and Services Does CYCC Offer?

• Discover and develop novel small molecule drugs for cancer and other diseases involving abnormal cell growth.
• Conduct Phase 1/2 clinical trials for Fadraciclib, a CDK inhibitor, for solid tumors and chronic lymphocytic leukemia.
• Advance CYC140, a PLK inhibitor, through Phase 1/2 clinical trials for advanced leukemias and solid malignancies.
• Evaluate Sapacitabine, an orally available nucleoside analog, in Phase 1/2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome.
• Support investigator-sponsored trials (ISTs) for Seliciclib, a CDK inhibitor, in Cushing's disease and advanced rheumatoid arthritis.
• Collaborate with the University of Texas MD Anderson Cancer Center to clinically assess pipeline compounds in blood cancers.
• Focus on therapeutic areas with high unmet medical needs, particularly in oncology.

How Does CYCC Make Money?

• Primarily focused on research and development of clinical-stage drug candidates, with no current commercialized products generating significant revenue.
• Future revenue generation is anticipated through successful clinical development, regulatory approval, and subsequent commercialization of drug candidates, either independently or through licensing agreements and partnerships.
• Engages in strategic alliances, such as with MD Anderson, to advance clinical trials and leverage external expertise and resources.
• Relies on capital raises and grants to fund ongoing research, clinical trials, and operational expenses.

What Industry Does CYCC Operate In?

Cyclacel Pharmaceuticals, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on oncology and diseases involving abnormal cell growth. The broader healthcare sector is characterized by continuous innovation, significant R&D investment, and stringent regulatory oversight. The market for cancer therapeutics is substantial and growing, driven by an aging global population and advancements in understanding disease mechanisms. Cyclacel's positioning as a clinical-stage company means it is at the forefront of drug discovery, aiming to develop novel small molecule inhibitors, such as CDK and PLK inhibitors, which represent a significant area of research in targeted cancer therapies. The competitive landscape includes numerous large pharmaceutical companies and smaller biotech firms with extensive pipelines. Cyclacel differentiates itself through its specific drug targets and its strategic alliance with institutions like MD Anderson, which can accelerate clinical development and provide access to specialized expertise, crucial for navigating the complex path from discovery to commercialization.

Who Are CYCC's Key Customers?

• Currently, patients participating in clinical trials for various cancers and diseases involving abnormal cell growth.
• In the future, patients diagnosed with solid tumors, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome, Cushing's disease, and advanced rheumatoid arthritis, pending drug approvals.
• Healthcare providers and oncologists who would prescribe approved therapies.
• Potential pharmaceutical partners seeking to license or acquire novel drug candidates for specific therapeutic areas.

Company Profile

Cyclacel Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Berkeley Heights, US. The company is led by CEO Sing Ee Wong. CYCC has traded publicly since 2004.

F-Score 3/9Financial Health

Cyclacel Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ROE -51%Key Financial Metrics

Return on equity for Cyclacel Pharmaceuticals, Inc. stands at -51.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -90.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -62.7%, the inverse of the P/E and a quick read on earnings relative to price.

CYCC Valuation & Market Position

With a $10.61M market cap, Cyclacel Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CYCC's quantitative score of 43/100 is below the peer average of 76/100.

FY2026 estForward Outlook

Wall Street analysts project Cyclacel Pharmaceuticals, Inc. revenue of about $100K for fiscal 2026, with EPS near $-268.80.

CYCC Financials

CYCC Latest News

CYCC Analyst Consensus

CYCC MoonshotScore

CYCC Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources